{"id":80438,"date":"2023-12-08T17:49:17","date_gmt":"2023-12-08T17:49:17","guid":{"rendered":"https:\/\/cri1149.fr\/publication\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\/"},"modified":"2023-12-08T17:49:17","modified_gmt":"2023-12-08T17:49:17","slug":"prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial","status":"publish","type":"publication","link":"https:\/\/cri1149.fr\/en\/publication\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\/","title":{"rendered":"Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24\/CCTG PA6 Clinical Trial"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false},"category_publication":[],"class_list":["post-80438","publication","type-publication","status-publish","hentry"],"acf":{"numero_de_publication":"J Clin Oncol.","date_de_publication":"20231114","numero_doi":"","equipe":[387],"auteurs-liste":[{"texte_libre":false,"auteur-lien":47152,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Jean-Baptiste Bachet"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Alexandre Harl\u00e9"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Juan Iovanna"},{"texte_libre":false,"auteur-lien":13087,"auteur-text":""},{"texte_libre":false,"auteur-lien":13146,"auteur-text":""},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Anthony Turpin"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Meher Ben Abdelghani"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Alice Wei"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Emmanuel Mitry"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Anthony Lopez"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"James Biagi"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Eric Fran\u00e7ois"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Pascal Artru"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Aur\u00e9lien Lambert"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Daniel J Renouf"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Laure Monard"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Marjorie Mauduit"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Nelson Dusetti"},{"texte_libre":true,"auteur-lien":null,"auteur-text":"Thierry Conroy"},{"texte_libre":false,"auteur-lien":13055,"auteur-text":""}],"auteurs-manuel":"","liens_externes":null,"liens":[{"lien":"https:\/\/pubmed.ncbi.nlm.nih.gov\/37963313\/"}],"paragraphe":"<div><img class=\" wp-image-72171 aligncenter\" src=\"https:\/\/cri1149.fr\/wp-content\/uploads\/2023\/12\/Papier-Remy-bandeau-12-2023-e1702054479446-300x137.png\" alt=\"\" width=\"725\" height=\"331\"><\/div>\n<div> <\/div>\n<div style=\"text-align: justify;\">This study evaluates the value of a transcriptomic signature, GemPred, to predict gemcitabine sensitivity in patients with resected pancreatic ductal adenocarcinoma (PDAC). This signature provides evidence of the possibility to uncover and apply clinically phenotyping tools for personalized medicine. <\/div>\n<div style=\"text-align: justify;\"> <\/div>\n<div style=\"text-align: justify;\">The study demonstrated that patients classified as GemPred+, indicating a high likelihood of gemcitabine response, experienced significantly better disease-free and cancer-specific survival compared to those categorized as GemPred\u2013. GemPred+ patients exhibited similar survival outcomes regardless of whether they received gemcitabine or a more aggressive chemotherapy regimen. <\/div>\n<div style=\"text-align: justify;\"> <\/div>\n<div style=\"text-align: justify;\">These findings highlight the potential of GemPred and more generally the transcriptome to guides patient treatment decisions, enabling to select the most effective and least toxic therapy for each individual patient. <\/div>","paragraphe_en":"","documents":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24\/CCTG PA6 Clinical Trial - CRI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cri1149.fr\/publication\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24\/CCTG PA6 Clinical Trial - CRI\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cri1149.fr\/publication\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"CRI\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/publication\\\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/publication\\\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\\\/\",\"name\":\"Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24\\\/CCTG PA6 Clinical Trial - CRI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#website\"},\"datePublished\":\"2023-12-08T17:49:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/publication\\\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cri1149.fr\\\/publication\\\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/publication\\\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cri1149.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\\\/\\\/cri1149.fr\\\/publications\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24\\\/CCTG PA6 Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#website\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/\",\"name\":\"CRI - Centre de Recherche sur l'Inflammation\",\"description\":\"Centre de Recherche sur l&#039;Inflammation\",\"publisher\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cri1149.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#organization\",\"name\":\"CRI1149\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cri1149.fr\\\/wp-content\\\/uploads\\\/2014\\\/11\\\/8.4.2014-logo-CRI.jpg\",\"contentUrl\":\"https:\\\/\\\/cri1149.fr\\\/wp-content\\\/uploads\\\/2014\\\/11\\\/8.4.2014-logo-CRI.jpg\",\"width\":215,\"height\":176,\"caption\":\"CRI1149\"},\"image\":{\"@id\":\"https:\\\/\\\/cri1149.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/CRI-Centre-de-recherche-sur-linflammation-100116118884153\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/cri-centre-de-recherche-sur-l-inflammation\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24\/CCTG PA6 Clinical Trial - CRI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cri1149.fr\/publication\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24\/CCTG PA6 Clinical Trial - CRI","og_url":"https:\/\/cri1149.fr\/publication\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\/","og_site_name":"CRI","article_publisher":"https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cri1149.fr\/publication\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\/","url":"https:\/\/cri1149.fr\/publication\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\/","name":"Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24\/CCTG PA6 Clinical Trial - CRI","isPartOf":{"@id":"https:\/\/cri1149.fr\/#website"},"datePublished":"2023-12-08T17:49:17+00:00","breadcrumb":{"@id":"https:\/\/cri1149.fr\/publication\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cri1149.fr\/publication\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cri1149.fr\/publication\/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable-pancreatic-adenocarcinoma-using-the-gempred-rna-signature-an-ancillary-study-of-the-prodige-24-cctg-pa6-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cri1149.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/cri1149.fr\/publications\/"},{"@type":"ListItem","position":3,"name":"Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24\/CCTG PA6 Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/cri1149.fr\/#website","url":"https:\/\/cri1149.fr\/","name":"CRI - Centre de Recherche sur l'Inflammation","description":"Centre de Recherche sur l&#039;Inflammation","publisher":{"@id":"https:\/\/cri1149.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cri1149.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cri1149.fr\/#organization","name":"CRI1149","url":"https:\/\/cri1149.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cri1149.fr\/#\/schema\/logo\/image\/","url":"https:\/\/cri1149.fr\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","contentUrl":"https:\/\/cri1149.fr\/wp-content\/uploads\/2014\/11\/8.4.2014-logo-CRI.jpg","width":215,"height":176,"caption":"CRI1149"},"image":{"@id":"https:\/\/cri1149.fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CRI-Centre-de-recherche-sur-linflammation-100116118884153","https:\/\/www.linkedin.com\/company\/cri-centre-de-recherche-sur-l-inflammation\/"]}]}},"_links":{"self":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/publication\/80438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/types\/publication"}],"acf:term":[{"embeddable":true,"taxonomy":"equipes","href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/equipes\/387"}],"wp:attachment":[{"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/media?parent=80438"}],"wp:term":[{"taxonomy":"category_publication","embeddable":true,"href":"https:\/\/cri1149.fr\/en\/wp-json\/wp\/v2\/category_publication?post=80438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}